Allogeneic NK platform technology targeting solid and blood based cancers… that ticks a lot of boxes!
pipeline is young, but now even more promising… with combination therapies going into development using our CLTX CAR-T.
trials expected to commence in 2023, so still a while away.. but still a lot of preclinical newsflow to derisk the asset between now and then.
plenty more reading material over the summer!
great company in the making, with opportunities to accumulate before CLTX cohort 2 data lands mid 2022… which couldn’t come soon enough.
goodluck all
Ann: Transformative Portfolio Expansion Presentation, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |